A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
NCT06143891
Recruiting
This is a parallel, Phase 3, two-arm study for the treatment of newly diagnosed moderate or severe chronic GVHD. The study duration for a participant includes up to 4 weeks for screening; a treatment period until clinically meaningful cGVHD progression (defined as progression requiring addition of new systemic treatment for cGVHD), relapse/recurrence of the underlying disease, participant starts new systemic treatment for cGVHD or experiences an unacceptable toxicity, at the request of the part... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/21/2025
Locations: University of Arkansas for Medical Sciences-Site Number : 8400019, Little Rock, Arkansas +150 locations
Conditions: Chronic Graft Versus Host Disease
Register for Updates
A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections
NCT06369220
Recruiting
This study is designed to assess the comparative clinical utility of the point of care cobas® liat CT/NG/MG to current standard practices in the diagnosis and treatment of urogenital infections with Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: San Francisco City Clinic, San Francisco, California +3 locations
Conditions: Chlamydia Trachomatis Infection, Neisseria Gonorrhoeae Infection, Mycoplasma Genitalium Infection
Register for Updates
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
NCT06528301
Recruiting
This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: City of Hope, Duarte, California +5 locations
Conditions: Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), Lymphoma, Large B-Cell, Diffuse (DLBCL), Chronic Lymphocytic Leukemia (CLL)
Register for Updates
A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab
NCT06706817
Recruiting
The main objective of this study is to evaluate treatment outcomes of tezepelumab among participants with physician-determined surgery-eligible CRSwNP, with or without asthma. Study details include: 1. The study duration will be up to 40 weeks. 2. The treatment duration will be up to 24 weeks. 3. The visit frequency will be once every 4 weeks (Q4W).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
05/21/2025
Locations: Research Site, Newport Beach, California +44 locations
Conditions: Chronic Rhinosinusitis With Nasal Polyps
Register for Updates
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878
Recruiting
This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance therapy with RO7790121 in participants with moderately to severely active Crohn's disease (CD).
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
05/21/2025
Locations: Digestive Health Specialists of the Southeast (Gastroenterology Associates of Dothan) - Dothan, Dothan, Alabama +81 locations
Conditions: Moderately to Severely Active Crohns Disease
Register for Updates
BOLSTER: Learning New Skills to Thrive
NCT06936878
Recruiting
This research study is evaluating a new program called Building Out Lifelines for Safety, Trust, Empowerment, and Renewal or (BOLSTER), which was designed to support participants with a gynecological or gastrointestinal cancer and new and complex care needs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: Gastrointestinal Cancer, Gynecologic Cancer, Advanced Cancer
Register for Updates
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
NCT02974647
Recruiting
The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cell lymphomas. By blocking JAK, ruxolitinib may cause T or NK-cell lymphomas to shrink.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: University of Miami, Miami, Florida +9 locations
Conditions: Lymphoma
Register for Updates
Transcranial Alternating Current Stimulation (tACS) in Aphasia
NCT04375722
Recruiting
This study will assess the effects of transcranial alternating current stimulation (tACS) on language recovery after stroke as well as healthy language functions.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/21/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Aphasia, Stroke
Register for Updates
Formulating Expert Consensus Guidelines in Cancer Care Using the Delphi Method
NCT05054413
Recruiting
This study formulates consensus agreement on clinical key elements related to prostate cancer care that are critical for standardization and global reported using a robust Delphi technique, completely remote and electronic. The goal of this survey study is to have a panel of specialty-specific experts create a consensus agreement on a minimum set of key data elements for use in standardized reports. These recommendations would be used to develop standardized methods to report key data in electro... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
05/21/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Register for Updates
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
NCT05490446
Recruiting
This purpose of this study is to establish proof of concept of tebapivat in participants with LR-MDS in Phase 2a and to evaluate the effect of tebapivat on transfusion independence (TI) in participants with LR-MDS in phase 2b.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Innovative Clinical Research Institute Whittier, Lakewood, California +44 locations
Conditions: Myelodysplastic Syndromes
Register for Updates
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
NCT05898646
Recruiting
This phase II trial compares shorter-duration versus longer-duration maintenance therapy with daratumumab for improving survival in patients who have received initial treatment with daratumumab for light chain (AL) amyloidosis. Maintenance therapy is treatment that is given to help keep cancer from coming back after it has disappeared following initial therapy. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +1 locations
Conditions: AL Amyloidosis
Register for Updates
AXIOS™ Gastroenterostomy for Gastric Outlet Obstruction IDE
NCT06174805
Recruiting
To investigate the safety and technical success of EUS-guided gastroenterostomy (EUS-GE) using the AXIOSTM lumen-apposing Metal Stent for the management of symptoms associated with gastric outlet obstruction from malignant unresectable neoplasm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +9 locations
Conditions: Gastric Outlet Obstruction
Register for Updates